NanoViricides is trading 6.51% lower at $1.58, with no clearly reported company-specific negative catalyst identified for September 22, 2026.
- The latest company announcement, dated September 15, concerned the planned Phase II NV-387 Ebola trial in the Democratic Republic of Congo.
- The company website reports no September 22 stock-market explanation or confirmed trial-start update.
- The broader biotech sector is higher, so sector strength does not explain the decline.